The MYC proto-oncogenes encode a family of transcription factors that are among the most
commonly activated oncoproteins in human neoplasias. Indeed, MYC aberrations or …

Lineage plasticity, the ability of cells to transition from one committed developmental
pathway to another, has been proposed as a source of intratumoural heterogeneity and of …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and treatment-refractory
cancer. Molecular stratification in pancreatic cancer remains rudimentary and does not yet …

Lineage plasticity has emerged as an important mechanism of treatment resistance in
prostate cancer. Treatment-refractory prostate cancers are increasingly associated with loss …

Lineage plasticity, a process whereby cells change their phenotype to take on a different
molecular and/or histologic identity, is a key driver of cancer progression and therapy …

The tumor microenvironment plays a critical role in tumor growth, progression, and
therapeutic resistance, but interrogating the role of specific tumor-stromal interactions on …

MYC is a master transcriptional regulator that controls almost all cellular processes. Over the
last several decades, researchers have strived to define the context-dependent …

MYC is implicated in the development and progression of pancreatic cancer, yet the precise
level of MYC deregulation required to contribute to tumor development has been difficult to …

Although the estimated time for development of pancreatic ductal adenocarcinoma (PDA) is
more than 20 years, PDAs are usually detected at late, metastatic stages. PDAs develop …

Research on obesity-and diabetes mellitus (DM)-related carcinogenesis has expanded
exponentially since these two diseases were recognized as important risk factors for …